337 results on '"Faillie, Jean-Luc"'
Search Results
2. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
3. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
4. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data
5. Drug-induced hyperglycemia and diabetes
6. Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study
7. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study
8. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
9. Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
10. SAT-306 Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury
11. The discovery of hypoglycaemic sulphonamides – Montpellier, 1942
12. Efficacy of metformin on glycemic control and weight in drug-naive type 2 diabetes mellitus patients: A systematic review and meta-analysis of placebo-controlled randomized trials
13. Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database
14. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study
15. Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population
16. Diabetes and COVID-19
17. Diabète et COVID-19
18. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data
19. Drug-induced hyperglycemia and diabetes
20. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus
21. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases
22. Adverse reactions related to brentuximab vedotin use: A real-life retrospective study
23. Case–non-case studies: Principle, methods, bias and interpretation
24. Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes
25. Will the future of pharmacovigilance be more automated?
26. Les études cas–non cas : principe, méthodes, biais et interprétations
27. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
28. Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390
29. Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies
30. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events
31. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study
32. Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys
33. Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
34. Pharmacoepidemiology and its input to pharmacovigilance
35. L’apport de la pharmaco-épidémiologie à la pharmacovigilance
36. Le biais de temps immortel dans les études pharmacoépidémiologiques : définition, solutions et exemples
37. Parkinsonian Patients Requiring Proteasome Inhibitors for Multiple Myeloma: Exceptional Circumstances Call for Extra Caution
38. GLP-1 receptor agonists and the risk of thyroid cancer
39. Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database
40. Troubles de l’usage de l’alprazolam : une analyse de la base de données mondiale de pharmacovigilance VigiBase™
41. Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database
42. Immune checkpoint inhibitors induced liver injury: an observational study
43. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes : cohort study
44. Quinolone antibiotics and suicidal behavior: analysis of the World Health Organization’s adverse drug reactions database and discussion of potential mechanisms
45. New Formulation of Methadone for Opioid Dependence in France: Acceptability and Diversion/Misuse Liability
46. Slow-Release Oral Morphine Sulfate Abuse : Results of the Postmarketing Surveillance Systems for Psychoactive Prescription Drug Abuse in France
47. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
48. Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT).
49. Pioglitazone and the risk of bladder cancer: Risks seem to outweigh benefits as yet more evidence emerges
50. Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.